EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
SLD Summit 202321-23 September Prague
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| PO5-1 | Association of liver fibrosis with emerging extrahepatic cancer in fatty liver patients with the PNPLA3 I148M GG genotype: an 8-year cohort study | MINGLING CHANG |  Received |
 |
|||
| PO4-1 | Diagnosing metabolic associated steatotic liver disease in primary care patients with type 2 diabetes mellitus - a novel, algorithm based approach | Damien Leith | Received |
|
|||
| PO7-1 | Association between cardiovascular disease risk factors and metabolic dysfunction-associated steatotic liver disease among rheumatoid arthritis patients | Alina Saidi | Received |
|
|||
| PO3-1 | PNPLA3 is associated to FIB-4 but not to (cardiovascular) mortality in an elderly population: report from the PROSPER trial | Vivian de Jong | Received |
|
|||
| PO1-1 | DMF-activated Nrf2 ameliorates palmitic acid toxicity in hepatocytes while potentiates ferroptosis: independent protection by NO-donors | Diana Abu halaka | Received |
|
|||
| PO2-1 | Low implementation rates of the American Gastroenterology Association (AGA) clinical care pathway in gastroenterology practice. | Pollard Nina | Received |
|
|||
| PO6-1 | A 5 sit-to-stand test may identify MASLD patients at higher risk for worse clinical outcomes | Roberta Forlano | Received |
|
|||
| PO2-2 | Efficacy of metabolyteTM treatment for MASH prevention and reversal | Giulia Angelini | Received |
|
|||
| PO7-2 | Lobular inflammation, but no NAS score, is associated with higher risk of progression to cirrhosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) | Giordano Sigon | Received |
|
|||
| PO5-2 | The correlation between the LDL level and the development of NAFLD | MOHAMED SHAFI MAHBOOB ALI | Received |
|
|||
| PO4-2 | Diabetic advanced steatotic liver disease is a surrogate for the other complications of type 2 diabetes mellitus | Zülal Istemihan | Received |
|
|||
| PO1-2 | The impact of artificial intelligence on the evaluation of fibrosis changes in steatotic liver diseases: a single center experience | Reha Akpinar | Received |
|
|||
| PO3-2 | Steatotic liver disease and risk of hepatocellular carcinoma in hepatitis B and C infected individuals: a systematic review and meta-analysis | Muhammed Elfaituri | Received |
|
|||
| PO4-3 | The PNPLA3 genotype of MASLD patients profoundly alters their metabolic profile even with a low BMI | Lina Jegodzinski | Received |
|
|||
| PO6-3 | Association between hepatic artery resistance index (HARI), portal venous pulsatility index (PVPI) and steatotic liver disease (SLD) fibrotic score in SLD patients | Simu Razvan-Ioan | Received |
|
|||
| PO2-3 | RIPK3 modulates acyl chain structure in metabolic liver disease | André Cardador | Received |
|
|||
| PO7-3 | Disruption of hepatic integrity and lipid composition by hypercaloric diets in steatotic liver disease | Maria Joao Meneses | Received |
|
|||
| PO3-3 | Shared genetics between NAFLD and Parkinsons disease: the role of TLR4 signaling pathway | Christina Flourou | Received |
|
|||
| PO5-3 | Impact of exercise training on hepatic lipid composition in men with MASLD and impaired glycaemic regulation: a pilot randomised controlled trial | Sundus Malaikah | Received |
|
|||
| PO1-3 | The effects of vitamin E and docosahexaenoic acid ethyl ester on nonalcoholic fatty liver disease (NAFLD) - a randomized double blind placebo controlled parallel group clinical trial (PUVENAFLD) | Naim Alkhouri | Received |
|
|||
| PO6-4 | miR-21-5p promotes MASH-related hepatocarcinogenesis | Pedro Miguel Rodrigues | Received |
|
|||
| PO5-4 | Assessing hepatocellular senescence in metabolic dysfunction-associated liver disease using a quantitative approach | Roberta Forlano | Received |
|
|||
| PO3-4 | The natural history of metabolic dysfunction-associated steatotic liver disease with advanced fibrosis | Zouhir Gadi | Received |
|
|||
| PO7-4 | Liver steatosis and fibrosis in severe obesity in diabetic and non-diabetic subjects: first report of the Franciscus obesity NASH Study | Willy Theel | Received |
|
|||
| PO4-4 | Genetic markers of MASLD in an elderly Caucasian population and the association with obesity | Willy Theel | Received |
|
|||
| PO1-4 | The long term safety and efficacy of Saroglitazar in metabolic dysfunction-associated steatohepatitis (MASH) related compensated cirrhosis: a prospective, single center real life experience | Sujit Chaudhuri | Received |
|
|||
| PO5-5 | Transcriptomics driven metabolic pathway analysis to explore metabolic resemblance between metabolic-dysfunction associated steatohepatitis mouse models and human | Mojgan Masoodi | Received |
|
|||
| PO2-5 | Steatotic liver disease and SGLT2 inhibitors: improvement of hepatic fibrosis by Fibroscan in a prospective study | Jaqueline Curra | Received |
|
|||
| PO1-5 | Open data, explainable AI, data science and conventional NITs the recipe for new machine learning diagnostic tests on MASLD | Athanasios Angelakis | Received |
|
|||
| PO4-5 | Single-cell profiling of hepatic dendritic cells in metabolic dysfunction-associated steatotic liver disease | Camilla Klaimi | Received |
|
|||
| PO7-5 | Thermoacoustic assessment of fatty liver disease - a clinical feasibility study | Michael Thornton | Received |
|
|||
| PO6-5 | Changes in lipid metabolism and insulin resistance after an oral lipid load in patients with metabolic dysfunction associated steatotic liver disease (MASLD) carrying the PNPLA3 rs738409 polymorphism | Chiara Rosso | Received |
|
|||
| PO6-6 | Analytical and clinical comparison of three non-invasive tests for the diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) | Silvia Sabatini | Received |
|
|||
| PO1-6 | Validation of HeparDx score (by Metadeq, Inc.) as a non-invasive test for the diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) | Giulia Angelini | Received |
|
|||
| PO7-6 | Risk factors for progression in metabolic dysfunction-associated steatotic liver disease | Letitia Toma | Received |
|
|||
| PO4-6 | Unleashing the potential of phytocannabinoids in modulating sphingolipid homeostasis for the treatment of metabolic dysfunction-associated steatotic liver disease | Radka Kocvarova | Received |
|
|||
| PO2-7 | Transcriptomics-assisted phenotypic screening to identify novel drugs and targets for liver fibrosis | Elisabetta De Filippo | Received |
|
|||
| PO1-7 | Poor diet quality is associated with higher liver stiffness and higher cardiovascular risk in a cohort of Italian MASLD (metabolic dysfunction associated steatotic liver disease) outpatients | Rusi Chen | Received |
|
|||
| PO4-7 | MASLD and chronic viral hepatitis: baseline results from patients enrolled in the PITER HCV and HBV and HDV italian cohorts | Loreta A. Kondili | Received |
|
|||
| PO7-7 | Quantitative assessment of liver steatosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) based on plasma extracellular vesicles in correlation with ultrasound attenuation parameter (UAP). | Eleni Myrto Trifylli | Received |
|
|||
| PO6-7 | The association of liver fibrosis, insulin resistance and systemic leukocyte activation in obese patients | Alina Saidi | Received |
|
|||
| PO5-7 | Hypoxanthine plasma levels as a new potential non-invasive biomarker of metabolic-dysfunction associated steatotic liver disease | Melissa Maria Milito | Received |
|
|||
| PO3-7 | Behavioural specifics of patients living with non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease a key to improve communication | Andreas Geier | Received |
|
|||
| PO2-8 | Statin treatment reduces all-cause mortality in elderly with increased risk of liver fibrosis: report from the PROSPER trial | Vivian de Jong | Received |
|
|||
| PO4-8 | Comparison of the efficacy of MR spectroscopic and MR imaging methods for assessing liver fat changes in obese patients undergoing dietary intervention and GLP-1 agonist treatment | Petr Kordac | Received |
|
|||
| PO1-8 | Galectin-3 inhibitor prevents metabolic dysfunction-association steatohepatitis and insulin resistance in western diet-fed ApoE knockout mice | Layanne Araujo | Received |
|
|||
| PO6-8 | The potential role of Omentin-1 in metabolic-dysfunction associated steatotic liver disease (MASLD): evidence from translational studies | Noel Salvoza | Received |
|
|||
| PO7-8 | Novel compound SNP-6 series active metabolites mitigate nonalcoholic steatohepatitis and fibrosis: results from preclinical models and a phase 2a clinical trial | Chang-Hui Tsao | Received |
|
|||
| PO3-8 | Culturally adapting the mediterranean diet for the hispanic and latino population in the weight intervention in liver disease (WILD) clinical pathway | Sheena Gillani | Received |
|
|||
| PO5-8 | Assessment of liver fibrosis in individuals with inflammatory bowel disease and steatotic liver disease using non-invasive tests | Robert Nastasa | Received |
|
|||
| PO4-9 | Gender differences in the development of steatotic liver disease and fibrosis: implications for diagnosis and management | Florian Koutny | Received |
|
|||
| PO5-9 | SMAD 3 variant rs10152544 is associated with higher fibrosis grade in metabolic steatotic liver disease (MASLD) | Claudia Oliveira | Received |
|
|||
| PO3-9 | Staging chronic liver injury and fibrosis using the enzyme biomarkers circulating fibroblast activation protein alpha (cFAP) and cDPP4 | Mark Gorrell | Received |
|
|||
| PO6-9 | The impact of sarcopenia on both liver and cardiovascular alterations in patients with early stages of steatotic liver disease: a sole protagonist or a co-actor with other metabolic risk factors? | FLORIANA SANTOMENNA | Received |
|
|||
| PO2-9 | Assessing the repeatability and reproducibility of LiverMultiScan metrics cT1 and PDFF | Andrea Dennis | Received |
|
|||
| PO7-9 | Clinical and biochemical features of diagnosed and undiagnosed patients with non-alcoholic fatty liver disease | Julia Uhanova | Received |
|
|||
| PO1-9 | Pharmacodynamics screening of potential therapeutic substances in an experimental model of metabolic dysfunction associated steatohepatitis | Mahak Arora | Received |
|
|||
| PO6-10 | A randomized controlled trial of Resmetirom in nonalcoholic steatohepatitis: 52-week Data From MAESTRO-NASH | Peter Rydqvist | Received |
|
|||
| PO5-10 | Histological features distinguish alcoholic from metabolic dysfunction-associated steatohepatitis | Tessa Ostyn | Received |
|
|||
| PO4-10 | Treatment with semaglutide affects favorably hepatic fat content but has no effect on response of liver fat to glucose and/or fructose administration | Jan Kovar | Received |
|
|||
| PO2-10 | Hepatic steroids metabolism reflects the entity of liver damage in patients with metabolic dysfunction-associated steatohepatitis (MASH) | Eleonora Dileo | Received |
|
|||
| PO1-10 | Persons diagnosed with metabolic dysfunction-associated steatotic liver disease are at an increased risk of severe depression in a Swedish nationwide cohort study | Hanne ström | Received |
|
|||
| PO7-10 | GCKIII kinases in hepatocellular lipotoxicity: role in NAFLD and beyond | Margit Mahlapuu | Received |
|
|||
| PO3-10 | Serum protein induced by vitamin k absence or antagonist II for the prediction and risk stratification of HCC development in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up | Marta Guariglia | Received |
|
|||
| PO3-11 | Alcohol overconsumption is common in MASLD and highly increases risk for future cirrhosis | Hannes Hagström | Received |
|
|||
| PO1-11 | Cytokines level during the pregnancy with MASH and obesity under the developed complex therapy program | Lina Bahniy | Received |
|
|||
| PO4-11 | In silico strategies and gene expression data indicate EFEMP1 as a potential biomarker for early fibrosis diagnosis in metabolic dysfunction-associated steatotic liver disease | Allen Anthony Larańo | Received |
|
|||
| PO6-11 | The beneficial hepatic-effect of Glucagon-like Peptide 1 receptor agonists in diabetic patients with metabolic dysfunction-associated liver disease (MASLD) | Giordano Sigon | Received |
|
|||
| PO5-11 | Exploring the association between quality of life, diet, physical activity, and binge eating disorder in MASLD patients in a tertiary centre of care | Giordano Sigon | Received |
|
|||
| PO7-11 | Genetic evidence for a role of PON2 in liver fibrosis and generation of PON2 knockdown LX-2 cells | Tammy Huybrechts | Received |
|
|||
| PO2-11 | Adherence to mediterranean diet reduces steatotic liver disease risk but does not affect liver fibrosis assessed by transient elastography: results from a prospective study | Gediz Dogay Us | Received |
|
|||
| PO3-12 | Traditional indigenous land-based diet and non-alcoholic fatty liver disease | Julia Uhanova | Received |
|
|||
| PO7-12 | Glutamyl aminopeptidase A (APA): a novel secreted kidney protein impacting liver homeostasis | Sharleen Hamad | Received |
|
|||
| PO5-12 | Evaluation of non-invasive scores for monitoring liver fibrosis resolution after bariatric surgery | Francois Pattou | Received |
|
|||
| PO2-12 | Comparison of the prognosis of patients with metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease who underwent hepatic vein catheterization | imon Dostál | Received |
|
|||
| PO1-12 | Maternal overnutrition and increased risk of intergenerational liver disease and cancer targeting epigenetic mechanisms | Claudia Bigas | Received |
|
|||
| PO6-12 | Association between FAST score and hepatocyte ballooning in Non- Alcoholic steatohepatitis patients: findings from EVIDENCES-X study of 393 biopsied individuals | Deven Parmar | Received |
|
|||
| PO2-13 | Progression to cirrhosis and all-cause mortality is increased In postmenopausal women with MASLD independently of fibrosis stage at baseline | Aleksandra Dunin-Borkowska | Received |
|
|||
| PO6-13 | Estimated glucose disposal rate correlates with histological severity of MASLD in women, but not in men | Zouhir Gadi | Received |
|
|||
| PO5-13 | Early prediction of progressive fibrogenesis in participants with MASLD using blood-based biomarkers | Koen van Son | Received |
|
|||
| PO4-13 | Low number needed to screen for advanced MASLD fibrosis in internal medicine and general practice | Koen van Son | Received |
|
|||
| PO7-13 | Validation of the enhanced liver fibrosis (ELF)-test in heparinized and EDTA plasma for future reflex testing in diagnostic algorithms | Koen van Son | Received |
|
|||
| PO3-13 | CTRP1, a novel molecular linker for hepatic glycogen and lipid metabolism ameliorates fatty liver diseases | Sora Han | Received |
|
|||
| PO1-13 | Inflammatory landscape and metabolic profiling of the Mc4r KO mouse on a western diet to study human metabolic dysfunction associated steatohepatitis | Fabienne Birrer | Received |
|
|||
| PO7-14 | Cholesterol exacerbates microcirculatory abnomalities in non-alcoholic fatty liver disease | Evelyn Pereira | Received |
|
|||
| PO3-14 | Associations of the fibrosis-4 index with rates of cardiac events and liver decompensation, and the potential implications on risk stratification in patients with nonalcoholic steatohepatitis | Fishman Jesse | Received |
|
|||
| PO6-14 | Phosphatilylethanol probe into the de-novo post-liver transplant steatotic liver disease: MASLD, or MetALD? | Lubomir Skladany | Received |
|
|||
| PO5-14 | Impact of a 6-month dietary intervention on cognitive dysfunction and liver status in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease | Nuria Pérez Diaz del Campo | Received |
|
|||
| PO4-14 | Apolipoprotein F deficiency is associated with reduced mitochondrial function in hepatocytes | Viktor LIENARD | Received |
|
|||
| PO1-14 | Association of hepatic fibrosis and chronic kidney disease in a real world cohort of metabolic-dysfunction associated steatotic liver disease (MASLD); implications for screening in an intelligent LFT (iLFT) platform | Paul Brennan | Received |
|
|||
| PO2-14 | Loss of liver adrenoceptor alpha-1b exacerbates fibrosis and inflammation in mice | Bernie Efole | Received |
|
|||
| PO1-15 | STE20-type Kinases MST3 and MST4 promote the progression of hepatocellular carcinoma | Mara Caputo | Received |
|
|||
| PO2-15 | Hepatocellular loss of mTOR aggravates tumor burden in non-alcoholic steatohepatitis-related HCC | Antje Egners | Received |
|
|||
| PO6-15 | Diagnostic accuracy and optimal cut-off of fibroScan controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) in assessing steatosis and fibrosis in patients with bariatric surgery and elective laparoscopic cholecystectomy | Riham Soliman | Received |
|
|||
| PO5-15 | Metabolomics analysis showed increased metabolites and acylcarnitine concentrations before and after a lipid load in subjects with steatotic liver disease | SAMANTHA PEZZICA | Received |
|
|||
| PO4-15 | Multiparametric liver ultrasound for non-invasive quantification of steatosis, fibrosis, ballooning and inflammation in metabolic dysfunction-associated steatotic liver disease | Antonio Liguori | Received |
|
|||
| PO3-15 | Mechanisms underlying steatotic liver disease in mental illness: antipsychotic drugs disrupt ferroptosis signaling pathways | Karen Houseknecht | Received |
|
|||
| PO3-16 | Serum free fatty acids in children with metabolic-associated fatty liver fibrosis | Nataliya Zavhorodnia | Received |
|
|||
| PO6-16 | Steatotic liver disease and inflammatory bowel disease: is it all MASLD? | Patricia Sousa | Received |
|
|||
| PO4-16 | Non-invasive assessment of cell-free circulating mtDNA and copy number open an intriguing spyhole for the diagnosis of NAFLD-HCC in genetically predisposed individuals | Miriam Longo | Received |
|
|||
| PO1-16 | RIPK3-dependent signalling and crosstalk hepatocytes-macrophages in MASLD progression | André Cardador | Received |
|
|||
| PO2-16 | The effect of baseline hepatic steatosis on fibrosis changes after SVR in CHC-Genotype 4 patients treated with INF, a 10-year follow-up | Mohamed Elbasiony | Received |
|
|||
| PO5-16 | The role of genetic polymorphism in predicting of metabolic associated fatty liver disease clinical course | Vasyl Prysyazhnyuk | Received |
|
|||
| PO7-16 | Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes | Axel Wester | Received |
|
|||
| PO1-17 | SAMM50 affect mitochondria dynamics in high-fat related non-alcohol steatohepatitis | Wan-Long Chuang | Received |
|
|||
| PO7-17 | The efficacy of multi-disciplinary lifestyle modifications in Taiwanese non-alcoholic steatohepatitis patients- subgroup analysis of the placebo group patients in a randomized trial | Jee-Fu Huang | Received |
|
|||
| PO5-17 | Synergistic effect of metabolic dysfunction-associated steatotic liver disease and obesity severity in adolescents on future risk of type 2 diabetes: a cohort study | Resthie R Putri | Received |
|
|||
| PO6-17 | Effects of sodium-glucose cotransporter 2 inhibitor versus sulfonylurea on nonalcoholic fatty liver disease and diabetes | Yumie TAKESHITA | Received |
|
|||
| PO2-17 | Assessing the diagnostic accuracy of the fibroScan-AST (FAST) score for high-risk metabolic dysfunction-associated steatohepatitis : a diagnostic accuracy meta-analysis | Muhammed Elfaituri | Received |
|
|||
| PO3-17 | Transition from non-alcoholic fatty liver disease to steatotic live disease: real-world evidence in a cohort of individuals with type 1 and type 2 diabetes | Tammy Huybrechts | Received |
|
|||
| PO6-18 | Lipid and carbohydrate metabolism in children with metabolic-associated fatty liver fibrosis | Nataliya Zavhorodnia | Received |
|
|||
| PO4-18 | Metabolic-associated steatotic liver disease and insulin-related mechanisms: insights from a cluster analysis of the PREVADIAB2 study | Maria Paula Macedo | Received |
|
|||
| PO5-18 | Diagnostic accuracy of AGILE3 score for the non-invasive identification of patients with steatotic liver disease (SLD) and advanced fibrosis: a systematic review and meta-analysis | Federico Ravaioli | Received |
|
|||
| PO2-18 | The hepatokine leukocyte cell-derived chemotaxin-2 is elevated in people with impaired glycaemic control and augmented by acute exercise | Buket Engin | Received |
|
|||
| PO7-18 | Predictive ability of non-invasive fibrosis tests for long-term liver, cardiovascular and kidney outcomes in Europeans with metabolic risk factors from the UK Biobank | Federica Tavaglione | Received |
|
|||
| PO1-18 | Improvement of HRQoL features and liver status after a 6-month dietary intervention in patients with metabolic dysfunction-associated steatotic liver disease | Gabriele Castelnuovo | Received |
|
|||
| PO3-18 | The effect of dapagliflozin on fibrosis and inflammation in patients with metabolic dysfunction-associated steatohepatitis | Elena Laura Iliescu | Received |
|
|||
| PO5-19 | Combining diabetes, sex and menopause as meaningful clinical features associated with NASH and moderate-to-advanced liver fibrosis in uned individuals with class II and III obesity: a retrospective cohort study | Violeta Raverdy | Received |
|
|||
| PO4-19 | Depression, anxiety, worry and emotional dysregulation in compensated advanced chronic liver disease | Eleonora Maggio | Received |
|
|||
| PO3-19 | High tyrosine and PLIN2 and low beta-hydroxybutyrate characterize subjects with metabolic dysfunction-associated steatohepatitis (MASH) | Patrizia Infelise | Received |
|
|||
| PO1-19 | From old to new: assessing the accuracy of non-invasive tests of fibrosis in patients with metabolic associated fatty liver disease and excessive alcohol consumption according to the recent definition | Annalisa Cespiati | Received |
|
|||
| PO2-19 | Comparison between transient elastography and shear wave elastography for assessment of liver fibrosis in Egyptian patients with NAFLD: a single center experience | Ahmed/ El Fayoumi | Received |
|
|||
| PO-20 | Draft 1 | Carlos Vidal | Received |
|
|||
SLD Summit 2023
21-23 September Prague
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 21/09/2023 TO 21/09/2024
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
Poster submission deadline 11/09/2023
|
|
